BioAge Labs Files S-1/A for IPO

Ticker: BIOA · Form: S-1/A · Filed: Sep 18, 2024 · CIK: 1709941

Bioage Labs, INC. S-1/A Filing Summary
FieldDetail
CompanyBioage Labs, INC. (BIOA)
Form TypeS-1/A
Filed DateSep 18, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$17.00, $19.00, $15.0 million, $18.00, $150 billion
Sentimentneutral

Sentiment: neutral

Topics: ipo, pharmaceutical, sec-filing

TL;DR

BioAge Labs IPO filing updated. Get ready for some biotech action.

AI Summary

BioAge Labs, Inc. filed an S-1/A amendment on September 18, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to register its securities under the Securities Act of 1933. Its principal executive offices are located at 1445A South 50th Street, Richmond, California.

Why It Matters

This filing indicates BioAge Labs is moving forward with its plan to become a publicly traded company, which could provide it with significant capital for its pharmaceutical research and development efforts.

Risk Assessment

Risk Level: medium — As a pharmaceutical company pursuing an IPO, BioAge Labs faces inherent risks related to drug development, regulatory approval, and market acceptance.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1/A filing?

This is an Amendment No. 1 to a Form S-1 Registration Statement filed by BioAge Labs, Inc. to register securities for its initial public offering.

When was this amendment filed?

The amendment was filed with the Securities and Exchange Commission on September 18, 2024.

Where is BioAge Labs, Inc. headquartered?

The company's principal executive offices are located at 1445A South 50th Street, Richmond, California, 94804.

Who is the CEO of BioAge Labs, Inc.?

Kristen Fortney, Ph.D. is the Chief Executive Officer and President of BioAge Labs, Inc.

What is the Standard Industrial Classification for BioAge Labs, Inc.?

The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 4,480 words · 18 min read · ~15 pages · Grade level 14.3 · Accepted 2024-09-18 16:04:14

Key Financial Figures

Filing Documents

Risk Factors

Risk Factors 17 Special Note Regarding Forward Looking 77 Market and Industry Data 79

Use of Proceeds

Use of Proceeds 80 Dividend Policy 82 Capitalization 83

Managements Discussion and Analysis of Financial Condition and Results

Managements Discussion and Analysis of Financial Condition and Results of Operations 88

Business

Business 108 Management 167 Page

Executive Compensation

Executive Compensation 176 Certain Relationships and Related Party Transactions 190 Principal Stockholders 193

Description of Capital Stock

Description of Capital Stock 196 Shares Eligible for Future Sale 203 Material U.S. Federal Income Tax Consequences to Non-U.S. Holders 206

Underwriting

Underwriting 211 Legal Matters 220 Experts 220 Where You Can Find Additional Information 220 Index to Consolidated Financial Statements F-1 Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters do not take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or the time of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. Through and including , 2024 (the 25th day after the date of this prospectus), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing